Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Extrapulmonary CT Findings Predict In-Hospital Mortality in COVID-19. A Systematic Review and Meta-Analysis

Hans-Jonas Meyer, MD, Andreas Wienke, PhD, Alexey Surov, MD

Rationale and Objectives: Several prognostic factors have been identified for COVID-19 disease. Our aim was to elucidate the influence of non-pulmonary findings of thoracic computed tomography (CT) on unfavorable outcomes and in-hospital mortality in COVID-19 patients based on a large patient sample.

Materials and Methods: MEDLINE library, Cochrane and SCOPUS databases were screened for the associations between CT-defined features and mortality in COVID-19 patients up to June 2021. In total, 22 studies were suitable for the analysis, and included into the present analysis. Overall, data regarding 4 extrapulmonary findings could be pooled: pleural effusion, pericardial effusion, mediastinal lymphadenopathy, and coronary calcification.

Results: The included studies comprised 7859 patients. The pooled odds ratios for the effect of the identified extrapulmonary findings on in-hospital mortality are as follows: pleural effusion, 4.60 (95% CI 2.97–7.12); pericardial effusion, 1.29 (95% CI 0.83–1.98); coronary calcification, 2.68 (95% CI 1.78–4.04); mediastinal lymphadenopathy, 2.02 (95% CI 1.18–3.45).

Conclusion: Pleural effusion, mediastinal lymphadenopathy and coronary calcification have a relevant association with in-hospital mortality in COVID-19 patients and should be included as prognostic biomarker into clinical routine.

Key Words: Meta analysis; Systematic review; CT; COVID-19.

© 2021 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Rationale and Objectives

The prevalent coronavirus disease 2019 (COVID-19) pandemic has spread throughout the world and is considered a serious threat to global health.

The clinical course of COVID-19 is highly variable. Early during the pandemic, it was identified that most patients have a mild disease course with little or even no symptoms, but a minority of patients rapidly deteriorates to a severe or critical illness with need of admission to an intensive care unit, and even a fatal outcome (1–4). The case fatality rate during the first peak of the pandemic was over 10% in most European countries (2). Therefore, prediction of unfavorable courses of COVID-19 can be crucial for patient care, especially during early stages of the disease (2).

Already established prognostic factors are age and sex with the reported hazard ratios of 2.6 for age over 60 years and 1.4 for male sex (5,6). Moreover, a shorter time period between symptom onset and emergency room presentation is also a prognostic factor (2). Comorbidities including dementia, heart failure, and peripheral vascular diseases are also predictors of an unfavourable course of the disease (6).

Computed tomography (CT) is the diagnostic imaging modality of choice in COVID-19, especially for detection of pulmonary consolidations (2,7,8). In cases suspicious for COVID-19, it can be acquired without administration of contrast media, and in low-dose technique (7). Typical imaging findings of COVID-19 were already reported in the early stages of the pandemic (4). The pulmonary consolidations were described as bilateral, peripheral dominant ground-glass opacities with lower lobe, and posterior predilection (7).

Extrapulmonary findings, comprising pleural effusion, pericardial effusion, mediastinal lymphadenopathy, were described as atypical, and should raise the concerns for
possible differential diagnoses (7). However, there were published data, that even these rare findings in COVID-19 patients exist, and can predict a more severe or lethal course of the disease (9).

Since the early days of the pandemic, the introduction of vaccination has changed the course of the pandemic, but lethal COVID-19 cases still exist, and correct diagnosis and treatment are still highly relevant throughout different countries (10-12).

Early prediction of an unfavourable course of COVID-19 cases is important to improve clinical treatment, such as appropriate triaging, if needed, early admission to ICU, and expanding more aggressive treatment, e.g. with extracorporeal membrane oxygenation.

The purpose of the present systematic review and meta-analysis was to calculate the impact of CT-derived extrapulmonary features with in-hospital mortality in COVID-19 patients.

METHODS

Data Acquisition

MEDLINE library, Cochrane and SCOPUS databases were screened for CT findings and in-hospital mortality in COVID-19 patients up to June 2021. The paper acquisition is summarized in Figure 1.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used for the analysis (13).

The studies were screened for potential prognostic CT findings. Most studies reported prognostic relevance of pleural effusion, pericardial effusion, mediastinal lymphadenopathy, and coronary calcification. These findings were used for further analyses.

The following search words were used: “COVID-19” AND “Computed Tomography” OR “CT” AND “mortality” OR “severe course” OR “death.”

The primary endpoint of the systematic review was the odds ratio of CT findings on mortality.

Studies (or subsets of studies) were included if they satisfied the following criteria: (1) COVID-19 diagnosis by PCR-RT, (2) reported CT findings (3) reported odds ratio or hazard ratio with confidence interval (CI). Exclusion criteria were (1) systematic reviews, (2) case reports, (3) non-English language, (4) other imaging modalities than CT.

In total, 22 studies were suitable for the analysis, and included into the present study (14-35).

Data Extraction

Data extraction was performed by HJM followed by an independent evaluation of extractions for correctness (AS). For each study, details regarding study design, year of publication, country of origin, patient number, patient characteristics (age and sex), diagnosis, treatment, CT findings, timepoint of the CT acquisition, survival outcome results, and adjustment factors were extracted.

Quality Assessment

The quality of the included studies was assessed by the Newcastle-Ottawa Scale (NOS) (36). Study quality assessment was conducted by two authors (HJM, AS), and mainly included the selection of cases, comparability of the cohort, and outcome assessment of exposure to risks. A score of 0–9 was assigned to each study, and a study with score ≥6 was considered to be of high quality.

Statistical Analysis

The meta-analysis was performed using RevMan 5.3 (2014; Cochrane Collaboration, Copenhagen, Denmark). Heterogeneity was calculated by means of the inconsistency index I² (37,38). DerSimonian and Laird random-effect models with inverse variance weights were performed without any further correction (39). Possible publication bias was assessed with funnel plot and Egger test.

Additionally, sub-analyses were performed to test possible heterogeneities caused by different CT techniques (16 slices vs 128 and 256 slices), and by the origin of the studies.

RESULTS

Quality of The Included Studies

Of the included 22 studies, 21 were retrospective (95.4%), and one was prospective (4.6%) (20). Table 1 gives an overview of the included articles.

The overall risk of bias can be considered as low, indicated by the high NOS values among the studies ranging from 5 to 8 points (Table 2). Two studies (15,25) did not report the exact patient recruitment duration, which can result in a potential bias. The exact CT timing was not reported sufficiently in several studies, which can be another bias. Funnel plot displays a publication bias (Fig 2).

Patients

The included studies comprised 7859 patients. There were 4713 men (60%) and 3146 women (40%), with a mean age of 59.6 years ranging from 44.2 to 70 years. In all studies, COVID–19 was diagnosed with RT-PCR.

Overall, 19 studies (86.4%) investigated patients during the first wave of the pandemic, two studies (9.1%) did not report the exact time-period (15,25). Most studies investigated patients between March and April 2020. Only one study analyzed cases after the first wave with inclusion of patients between September and October 2020 (14).

In 15 studies (68.2%) performed CT at the presentation of the admission or within 24 hours after admission. In 6 studies
(27.3%) the timepoint of the CT was not clearly stated within the manuscript. In one study (30) investigating coronary calcifications, CTs of the patients were included up to 5 years prior to admission.

Thirteen studies (59.1%) were performed in Asia, six studies (27.3%) in Europe, and three studies (13.6%) in North America. Table 3 provides an overview of the investigated sub-analyses according to study origin.

### Pleural Effusion

Overall, 15 studies with 3623 patients analyzed the effect of pleural effusion on in-hospital mortality in COVID-19 patients. The pooled odds ratio for the association between pleural effusion and in-hospital mortality was 4.6 (95% CI 2.97-7.12) (Fig3a).

On the next step, the reported data were analysed in accordance on study origin. Three studies with 772 patients were performed in Europe. The pooled odds ratio was 5.89 (95% CI 1.83-18.94) (Fig 3b). Two studies with 1303 patients were performed in China. The pooled odds ratio was 15.04 (95% CI 3.72-60.82) (Fig 3c). Finally, eight studies with 1158 patients were performed in Iran. The pooled odds ratio was 3.43 (95% CI 1.96-5.99) (Fig 3d).

Also, a sub-analysis of the data according to the used CT scanners was performed.

In seven studies with 1184 patients, 16 slices CT scanners were used. The pooled odds ratio was 5.26 (95% CI 2.62-10.56) (Fig 3e). In two studies with 757 patients, 128 or 256...
| Authors           | Country | Study design | Time period of the study | Mean age, years | Gender, female, n (%) | Included patients, n | Patients with CT-finding, n (%) | CT scanner | Time frame of CT acquisition |
|------------------|---------|--------------|--------------------------|----------------|-----------------------|---------------------|-------------------------------|------------|----------------------------|
| Abkhoo et al., 2021 | Iran    | Retrospective | September-October 2020   | 62.2           | 39 (32.2)             | 121                 | 30 (24.8) pleural effusion, 13 (10.7) pericardial effusion | 6-16 slices | Chest CT at base line       |
| Abrishami et al., 2020 | Iran    | Retrospective | Unclear                  | 60.6           | 15 (34.9)             | 43                  | 9 (20.9) pleural effusion, 29 (8) mediastinal lymphadenopathy (unclear threshold) | 64-slices | Chest CT with unclear timing |
| Ashtari et al., 2021 | Iran    | Retrospective | March -April 2020        | 61.6           | 95 (26.2)             | 363                 | 41 (11.3) pleural effusion | 16-slices | Chest CT at base line       |
| Chon et al., 2020 | South Korea | Retrospective | February 22-April 3 2020 | 61.5           | 206 (73.3)            | 281                 | 13 (4.6) pleural effusion | 128-slices | Chest CT at base line       |
| Eslami et al., 2020 | Iran    | Retrospective | February 20-April 10 2020| 54.5           | 30 (35.5)             | 87                  | 15 (17.2) Pericardial effusion | 64-slices | Chest CT at base line       |
| Giannini et al., 2021 | Italy  | Retrospective | March 1-April 20 2020    | 68             | 352 (31.7)            | 1093                | 734 (67.2) coronary calcification | Different scanner, 16-128 slices | Chest CT at base line       |
| Grodecki et al., 2021 | USA    | Prospective   | January 10-April 14 2020 | 64             | 41 (38)               | 109                 | 15 (13.8) pleural effusion | Different scanner, 16-128 slices | Chest CT at base line       |
| Gupta et al., 2021 | USA     | Retrospective | March 1-April 27 2020    | 68             | 82 (46)               | 180                 | 129 (71.7) coronary calcification | Different scanner, 64-256 slices | Chest CT at base line       |
| Khosravi et al., 2021 | Iran    | Retrospective | February 18-April 19 2020| 43% of patients | 54 (44.6)            | 121                 | 26 (21.7) pleural effusion, 18 (14.9) pericardial effusion, 6 (5) mediastinal lymphadenopathy (>10 mm) | 16-slices | Chest CT at base line       |
| Meiler et al., 2020 | Germany | Retrospective | March 1-April 15 2020    | 57.2           | 24 (38)               | 64                  | 13 (20) pleural effusion, 18 (28) mediastinal lymphadenopathy (>10 mm) | 16 and 128-slices | Chest CT at base line, 20% with contrast media |

(continued on next page)
| Authors                     | Country       | Study design  | Time period of the study       | Mean age, years | Gender, female, n (%) | Included patients, n | Patients with CT-finding, n (%) | CT scanner | Time frame of CT acquisition |
|-----------------------------|---------------|---------------|---------------------------------|-----------------|----------------------|----------------------|-------------------------------|------------|-----------------------------|
| Mozafari et al., 2021       | Iran          | Retrospective | February 29-April 3 2020        | 50.6            | 100 (46.9)            | 213                  | 7 (3.3) pleural effusion       | 16-slices | Chest CT at base line       |
| Mruk et al., 2021          | Poland        | Retrospective | Unclear                        | 56.7            | 67 (42.9)             | 156                  | 12 (7.7) pleural effusion      | 16-slices | Chest CT at base line       |
| Satici et al., 2021         | Turkey        | Retrospective | April 2-May 15 2020             | 56.9            | 317 (49.8)            | 650                  | 60 (9.2) mediastinal lymphadenopathy (> 10 mm) | 128-slices | Chest CT at base line       |
| Sattarzadeh Badkoubeh et al., 2021 | Iran          | Retrospective | March 5-March 27 2020           | 58.8            | 34 (39.5)             | 86                   | 5 (5.8) pericardial effusion   | Unclear    | Chest CT with unclear timing |
| Schiaffino et al., 2021     | Italy         | Retrospective | February 21-April 30 2020       | 65              | 188 (34)              | 552                  | 39 (7) pleural effusion        | Different scanners 16-128 slices | Chest CT within 24 h of admission |
| Scoccia et al., 2021        | Italy         | Retrospective | March 1-April 24 2020           | 69              | 533 (32.8)            | 1625                 | 1121 (69.0) coronary calcification | Different scanner, at least 16 slices | Chest CT with unclear timing |
| Slipszuk et al., 2021       | USA           | Retrospective | March 1-June 26 2020            | 70              | 249 (51.5)            | 493                  | 308 (67.7) coronary calcification | Different scanners 16-128 slices | Chest CT during or 5 years prior to admission |
| Tabatabaei et al., 2020     | Iran          | Retrospective | February 20-March 2 2020        | 54.9            | 50 (41.7)             | 120                  | 20 (16.7) pleural effusion     | 16-slices | Chest CT at baseline        |
| Tabatabaei et al., 2020     | Iran          | Retrospective | February 20-April 19 2020       | 44.2            | 36 (40)               | 30 deceased patients with 60 matched controls | 14 (15.6) pleural effusion | 16-slices | Chest CT with unclear timing |
| Wei et al., 2021            | China         | Retrospective | January 20-February 29 2020     | 50.9            | 376 (45.5)            | 827                  | 76 (9.2) pleural effusion Unclear | Unclear    | Chest CT with unclear timing |
| Zhan et al., 2021           | China         | Retrospective | January 20-March 23 2020        | 62.3            | 223 (46.8)            | 476                  | 153 (32.1) pleural effusion    | 64-slices | Chest CT at baseline        |
| Zimmermann et al., 2020     | Germany       | Retrospective | March 5-April 15 2020           | 61.8            | 35 (32.1)             | 109                  | 69 (63.3) coronary calcifications | 64 and 256 slices | Chest CT with unclear timing |

Abbreviations: CT, Computed tomography.
| Study                             | Is the case definition adequate | Representativeness of the cases | Selection of Controls | Definition of Controls | Comparability of cases and controls on the basis of the design or analysis | Ascertainment of exposure | Same method of ascertainment for cases and controls | Non-Response rate | Quality Score |
|----------------------------------|---------------------------------|---------------------------------|-----------------------|------------------------|-----------------------------------------------------------------|--------------------------|--------------------------------------------------|------------------|---------------|
| Abkhoo et al., 2021              | *                               | *                               | *                     | *                      | *                                                               | *                        | *                                                               | *                | 6             |
| Abrishami et al., 2020           |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 5             |
| Ashtari et al., 2021             |                                 | *                               |                       |                        | *                                                               | *                        | *                                                               | *                | 7             |
| Chon et al., 2020                |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 7             |
| Eslami et al., 2020              |                                 |                                 | *                     | *                      | *                                                               | *                        | *                                                               | *                | 8             |
| Giannini et al., 2021            |                                 |                                 | *                     | *                      | *                                                               | *                        | *                                                               | *                | 8             |
| Grodecki et al., 2021            |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 8             |
| Gupta et al., 2021               |                                 |                                 | *                     | *                      | *                                                               | *                        | *                                                               | *                | 8             |
| Khosravi et al., 2021            |                                 |                                 | *                     | *                      | *                                                               | *                        | *                                                               | *                | 8             |
| Meiler et al., 2020              |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 8             |
| Mozafari et al., 2021            |                                 |                                 | *                     | *                      | *                                                               | *                        | *                                                               | *                | 8             |
| Mruk et al., 2021                |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 5             |
| Satici et al., 2021              |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 7             |
| Sattarzadeh Badkoubeh et al., 2021|                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 7             |
| Schiaffino et al., 2021          |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 8             |
| Scoccia et al., 2021             |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 8             |
| Slipszuk et al., 2021            |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 8             |
| Tabatabaei et al., 2020          |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 8             |
| Tabatabaei et al., 2020          |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 8             |
| Wei et al., 2021                 |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 8             |
| Zhan et al., 2021                |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 7             |
| Zimmermann et al., 2020          |                                 |                                 |                       |                        | *                                                               | *                        | *                                                               | *                | 7             |

Abbreviation: NOS, Newcastle-Ottawa Scale
slices CT scanners were used. The pooled odds ratio was 15.04 (95% CI 3.72-60.82) (Fig 3f).

**Pericardial Effusion**

In five studies with 1508 patients the effect of pericardial effusion on in-hospital mortality in COVID-19 patients was investigated. The pooled odds ratio for the association between pericardial effusion and mortality was 1.29 (95% CI 0.83-1.98) (Fig 4).

No sub-analyses could be performed for pericardial effusion.

**Coronary Calcification**

In five studies (3500 patients) the effect of pericardial effusion on in-hospital mortality in COVID-19 patients was analyzed. The effect of coronary calcification was defined in all studies by presence of calcified plaques. The pooled odds ratio for the association between coronary calcification and mortality was 2.68 (95% CI 1.78-4.04) (Fig 5a).

Overall, three studies with 2827 patients were performed in Europe. The pooled odds ratio was 3.30 (95% CI 2.60-4.20) (Fig 5b). The remaining two studies with 673 patients were performed in the USA. The pooled odds ratio was 2.08 (95% CI 0.88-4.94) (Fig 5c).

**Mediastinal Lymphadenopathy**

In six investigations with 1906 patients the effect of pericardial effusion on in-hospital mortality in COVID-19 patients was studied. In 5 studies the threshold value of the short axis diameter was 10 mm, in one study (15) no threshold value was provided.

The pooled odds ratio for the association between mediastinal lymphadenopathy and mortality was 2.02 (95% CI 1.18-3.45) (Fig 6a).

Three studies with 772 patients originated from Europe countries. The pooled odds ratio was 2.77 (95% CI 1.12-6.87) (Fig 6b). The remaining two studies with 484 patients were performed in Iran. The pooled odds ratio was 0.94 (95% CI 0.44-2.01) (Fig 6c).

**TABLE 3. Overview of the Subanalyses of the Investigated CT Findings According to Study Origin**

| Origin                          | Female/male ratio (%) | Mean age in years |
|---------------------------------|-----------------------|-------------------|
| Pleural effusion                |                       |                   |
| Europe                          | 279/493 (36.1)        | 59.8              |
| China                           | 429/328 (56.7)        | 61.6              |
| Iran                            | 395/703 (36.0)        | 56.2              |
| Coronary Calcification          |                       |                   |
| Europe                          | 866/1750 (33.1)       | 64.3              |
| USA                             | 331/342 (49.2)        | 69                |
| Mediastinal Lymphadenopathy     |                       |                   |
| Europe                          | 279/493 (36.1)        | 59.3              |
| Iran                            | 149/335 (30.8)        | 61.0              |
DISCUSSION

This is the first meta-analysis regarding associations between non-pulmonary CT findings and mortality in COVID-19 patients. As shown, there was a statistically significant association of pleural effusion, coronary calcifications, and mediastinal lymphadenopathy with in-hospital mortality, whereas no significant association was identified with pericardial effusion. These findings highlight the importance of extrapulmonary findings in COVID-19 infection.

Figure 3. (a) Forrest plots of the odds ratios for the effect of pleural effusion on in-hospital mortality in COVID-19. The pooled odds ratio was 4.6 (95% CI 2.97-7.12). (b) The pooled odds ratio for pleural effusion in the studies from Europe was 5.89 (95% CI 1.83-18.94). (c) The pooled odds ratio for studies from China was 15.04 (95% CI 3.72-60.82). (d) The pooled odds ratio for pleural effusion in the studies from Iran was 3.40 (95% CI 1.96-5.99). (e) The pooled odds ratio for pleural effusion based on the studies used 16-sclice CT scanners was 5.26 (95% CI 2.62-10.56). (f) The pooled odds ratio for pleural effusion based on the studies used 128- and 256-sclice CT scanners was 15.04 (95% CI 3.72-60.82). (Color version of figure is available online.)
COVID-19 has a high mortality for patients with an unfavourable course. Thus, a short-term mortality of up to 20% was reported in COVID-19 patients admitted to the intensive care unit (ICU) (2-6,40). As mentioned previously, established prognosis parameters are age above 60 years and male sex, shorter period between symptom onset, and emergency room presentation (2-6,40). Moreover, the extension of pulmonary consolidation on CT images is also considered as prognostic relevant (2,41). The consolidations are indicative of a disease progression and are most prominent in day 10 of the disease (8).

The present analysis highlights the importance of CT for prognostic purposes beyond the quantification of pulmonary consolidations. Notably, the reported odds ratios are good comparable to the established risk factors, such as higher age over 60 years, and male sex (5), which highlights the importance of the extrapulmonary CT findings.

In a recent meta-analysis regarding CT findings in COVID-19, the time dependence of different CT findings was investigated (42). Pleural effusion and lymphadenopathy were more frequently identified in later disease stages (42). So far, pleural effusion was found in 5% of patients in early stages and in 16% of patients in advanced stages (42). Similarly, mediastinal lymphadenopathy was observed in 4% of patients in early stages and in 15% of patients in advanced stages (42). The time dependence may be a potential confounder of the
Figure 4. Forrest plots of the odds ratios for the effect of pericardial effusion on in-hospital mortality in COVID-19. (Color version of figure is available online.)

| Study or Subgroup | log(Odds Ratio) | SE  | Weight | Odds Ratio | Odds Ratio |
|-------------------|-----------------|-----|--------|------------|------------|
| Abdkhan 2021      | 1.954           | 1.06| 4.3%   | 7.68 [0.88, 66.35] |            |
| Badioubeh 2021    | 0.574           | 1.168| 3.8%   | 1.78 [0.18, 17.52] |            |
| Efamli 2021       | 0.438           | 0.73 | 9.2%   | 1.55 [0.37, 6.48]  |            |
| Giannini 2021     | 0.131           | 0.276| 64.0%  | 1.14 [0.86, 1.96]  |            |
| Khorasani 2021    | 0.119           | 0.598| 18.9%  | 1.13 [0.42, 3.05]  |            |
| Total (95% CI)    |                 |     |        | 100.0% | 1.29 [0.83, 1.98] |

Heterogeneity: 
\( \text{I}^2 = 0.00 \) \( \chi^2 = 2.96 \), \( df = 4 \) \( P = 0.56 \); \( \text{P} = 0 \%

Test for overall effect: \( Z = 1.14 \) \( P = 0.25 \)

Figure 5. (a) Forrest plots of the odds ratios for the effect of coronary calcification on in-hospital mortality in COVID-19. The pooled odds ratio was 2.68 (95% CI 1.78-4.04). (b) The pooled odds ratio for coronary calcification in the included investigations from Europe was 3.30 (95% CI 2.60-4.20). (c) The pooled odds ratio for coronary calcification in the included studies from the USA was 2.08 (95% CI 0.88-4.94). (Color version of figure is available online.)

(a) Forrest plots of the odds ratios for the effect of coronary calcification on in-hospital mortality in COVID-19. The pooled odds ratio was 2.68 (95% CI 1.78-4.04). (b) The pooled odds ratio for coronary calcification in the included investigations from Europe was 3.30 (95% CI 2.60-4.20). (c) The pooled odds ratio for coronary calcification in the included studies from the USA was 2.08 (95% CI 0.88-4.94). (Color version of figure is available online.)
present analysis. However, in most studies, CTs were performed at hospital admission.

Risk stratification of COVID-19 patients is very crucial for treatment planning. Important clinical parameters were identified, and several scores were proposed to predict mortality in COVID-19 (40). A recent study could show that a score based on serologically parameters comprising white blood cells, C-reactive protein, lymphocyte $\leq 0.8 \times 10^9/L$, and lactate dehydrogenase $\geq 400$ U/L was highly accurate to predict survival with an area under the curve of 0.95 (40).

Very early on during the pandemic, it was shown that cardiovascular co-morbidities, especially coronary heart disease are an important risk factor for a severe COVID-19 course (43). The present analysis can agree with this with a significant association between coronary calcification on CT images as an imaging finding of coronary heart disease. Clearly, there are cases of patients with amnestic known coronary heart disease without calcified plaques, which are not covered by this approach. Secondly, thoracic CT without contrast media application, and electrocardiogram triggering cannot be considered as a diagnostic gold standard for cardiac imaging. However, the sole presence of calcified plaques in CT performed for COVID-19 evaluation can be suspicious for an unfavorable outcome. Moreover, promising data indicated that quantification of coronary plaques using scores is even better to predict unfavorable outcomes (19,29). As a shortcoming of the present study, we could not pool the results of these plaque scores further due to differences in the included studies. To harmonize the data, we only include the dichotomized analyses of presence of coronary plaque or not.

Pleural effusion was the strongest predictor for mortality in the presented results. It was early on discussed as a rare finding.

Figure 6. (a) Forrest plots of the odds ratios for the effect of mediastinal lymphadenopathy on in-hospital mortality in COVID-19. The pooled odds ratio was 2.02 (95% CI 1.18-3.45). (b) The pooled odds ratio for mediastinal lymphadenopathy based on the acquired studies from Europe was 2.77 (95% CI 1.12-6.87). (c) The pooled odds ratio for mediastinal lymphadenopathy based on the collected reports from Iran was 0.94 (95% CI 0.44-2.01). (Color version of figure is available online.)
in patients with COVID-19 (44) and was stated to be more characteristic for other disorders, as pleural effusion is very common in critical ill patients. Clearly, there are many causes of pleural effusion, including viral pleuritis, congestive heart failure or cancer (33).

As early on stated, extrapulmonary imaging findings may indicate the occurrence of severe inflammation as identified by Li and colleagues (9). Another explanation was given that pleural effusion might indicate a bacterial superinfection as a severe complication of the COVID-19 infection.

In a comprehensive meta-analysis of prognostic factors in COVID-19, pleural effusion showed even a higher odds ratio for severe course, and mortality than pulmonary consolidation (OR of 3.31 versus 2.46) (45). However, this analysis only included studies up to April 2020, which could explain the different results to the present study.

Unfortunately, most studies did not report the size of the pleural effusion. It is yet unknown, whether the size has also a significant effect on mortality of COVID-19 patients.

Mediastinal lymphadenopathy is also an imaging finding, which was considered as rare in COVID-19 (7). It was also discussed as a possible sign for bacterial superinfection. The frequency of mediastinal lymphadenopathy was reported to be up to 29% (26). Of note, the frequency can differ according to the threshold value of enlargement. All included studies used 10 mm in short axis. In a recent study investigating 650 patients employed the threshold value of 10 mm, the frequency of mediastinal lymphadenopathy was 8.6% (26). The identified odds ratio for 30-days mortality in this mentioned study was 2.38 (95% 1.13-4.98) (26).

The only investigated CT finding not associated with mortality was pericardial effusion. In a small study based on 54 patients, a significant difference was identified between a severe and a critical patient group in regard of pericardial effusions (n = 1, 2.6%, n = 5, 33.3%, p < 0.01) (46). The presumed reason for the pericardial effusion was inflammatory effusion (46). Contrary to the present results, the authors used echocardiography, which might be more sensitive for detection of pericardial effusion in comparison to CT. According to Wang et al., cardiac injury caused by COVID-19 infection may also provoke pericardial effusion (3).

However, the present data can lead to the assumption that pericardial effusion is not a significant predictor for mortality.

Notably, the investigated studies included only patients of the first wave of the pandemic, which has a relevant impact on the results (47), as the mortality rates are declining since then. Due to less experience in care of COVID-19 patients and less knowledge of the disease in general, the course of COVID-19 patients might be worse than in recent days of the pandemic. Moreover, the possible effect of the current vaccination campaigns on COVID-19 mortality cannot be addressed by the present analysis.

The present analysis could show substantial differences between different origins of the investigated studies. This could explain the heterogeneity in this meta-analysis.

Interestingly, for pleural effusion, the pooled odds ratio was higher for studies from China compared to those in the studies performed in USA, Europe, and Iran. Furthermore, for coronary calcifications, no relevant difference between the studies from USA, and Europe were identified. Finally, for mediastinal lymphadenopathy, however, the pooled odds ratio was low in the sub-analysis for studies from Iran, whereas in the sub-analysis for studies from Europe, it was high. These findings are difficult to explain. Presumably, different virus subtypes may play a role. Another explanation may be the different beginning of the pandemic throughout the countries. China was the origin of COVID-19 and had less experience with this disease compared to the other world regions. There were also differences according to gender ratios and mean ages of the investigated patients.

The present meta-analysis has several limitations to address. First, it is comprised of published studies with between studies mainly caused by slightly different patient samples, and differ-ent study designs. Different countries with resulting different strategies for COVID-19 treatment and health care capabili-ties might also result in inhomogeneities. Second, there is the restriction to English language. Third, the presented results only rely on patient samples of the first wave of the pandemic. The results cannot be considered representative for the current state of the pandemic. Fourth, different CT scanner technology was used in the studies, ranging from 16 slices to 256 slices. There might be only small diagnostic accuracy differences between the different scanners used. One can consider the investigated CT findings of the present study as very stable to be accurately diagnosed on all CT scanners employed in clinical routine. Fourth, the included studies are restricted to COVID-19 patients, which were investigated by initial CT. This results in potential selection bias as most patients with COVID-19 are not diagnosed by CT. Forth, the exact timepoint of the CT was not clearly stated in 27.3% of studies. This could result in certain bias, when CT imaging was not performed at admission of the patients. However, in most studies CT was performed as a base line imaging directly at the admission of the hospital.

In conclusion, pleural effusion, coronary calcification, and mediastinal lymphadenopathy are associated with in-hospital mortality in COVID-19 patients. These extrapulmonary findings should be sufficiently reported by the radiologist and should be considered as highly clinically relevant.

ACKNOWLEDGEMENTS

None
REFERENCES

1. Chopra V, Flanders SA, Vaughn V, et al. Variation in COVID-19 character-
istics, treatment and outcomes in Michigan: an observational study in 32
hospitals. BMJ Open 2021; 11:e044921.
2. Besirli G, Ottone M, Fasano T, et al. Giorgi Rossi P; Reggio Emilia
COVID-19 working group. The value of computed tomography in assess-
ing the risk of death in COVID-19 patients presenting to the emergency
room. Eur Radiol 2021; 1–12.
3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized
patients with 2019 novel coronavirus-infected pneumonia in Wuhan,
China. JAMA 2020; 323:1061–1069.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
5. Liu B, Spokes P, He W, et al. High risk groups for severe COVID-19 in a
whole of population cohort in Australia. BMC Infect Dis 2021; 21:685.
6. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19
cases: a systematic literature review and meta-analysis. J Infect 2020;
81:e16–e25.
7. Kwee TC, Kwee RM. Chest CT in COVID-19: what the radiologist needs
to know. Radiographics 2020; 40:1848–1866.
8. Salehi S, Abedi A, Balakrishnan S, et al. Coronavirus disease 2019
(COVID-19): a systematic review of imaging findings in 919 patients. AJR
Am J Roentgenol 2020; 215:87–93.
9. Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with
severe and critical COVID-19 pneumonia. Invest Radiol 2020; 55:327–
331.
10. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. Eur J
Epidemiol 2020; 35:325–330.
11. Jakhmola S, Indari O, Kashyap D, et al. Recent updates on COVID-19: A
holistic review. Heliyon 2020; 6:e05706.
12. Cook TM, Roberts JV. Impact of vaccination by priority group on UK
deaths, hospital admissions and intensive care admissions from COVID-
19. Anaesthesia 2021; 76:608–616.
13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement:
an updated guideline for reporting systematic reviews. BMJ 2021; 372:
71.
14. Akbkooh A, Shaker E, Mehrabnejad MM, et al. Factors predicting out-
come in intensive care unit-admitted COVID-19 patients: using clinical,
laboratory, and radiologic characteristics. Crit Care Res Pract 2021;
2021:9941570.
15. Abrishami A, Khiali N, Dalili N, et al. Clinical and radiographic character-
istics of COVID-19 in patients with CKD. Iran J Kidney Dis 2020; 14:267–
277.
16. Ashhari S, Vahedian-Azimi A, Shojaee S, et al. Computed tomographic
features of coronavirus disease-2019 (COVID-19) pneumonia in three
groups of Iranian patients: a single center study. Radiology (Eng Ed)
2021; 65:314–323.
17. Chon Y, Kim JY, Suh YJ, et al. Adverse initial CT findings associated with
poor prognosis of coronavirus disease. J Korean Med Sci 2020; 35:e616.
18. Esfami V, Abrishami A, Zarei E, et al. The association of CT-measured
cardiac indices with lung involvement and clinical outcome in patients
with COVID-19. Acad Radiol 2021; 28:8–17.
19. Giannini F, Toselli M, Palisano A, et al. Coronary and total thoracic cal-
cium scores predict mortality and provides pathophysiologic insights in
COVID-19 patients. J Cardiovasc Comput Tomogr 2021; S1934-5925
(21):00032.
20. Grodecki K, Lin A, Razipour A, et al. Epidural adipose tissue is associ-
ated with extent of pneumonia and adverse outcomes in patients with
COVID-19. Metabolism 2021; 115:154436.
21. Gupta YS, Finkelstein M, Mannu S, et al. Coronary artery calcification
in COVID-19 patients: an imaging biomarker for adverse clinical outcomes.
Clin Imaging 2021; 77:1–8.
22. Khosravi B, Aghaghasavini L, Sorouri M, et al. Predictive value of initial CT
scan for various adverse outcomes in patients with COVID-19 pneumo-
ia. Heart Lung 2021; 50:13–20.
23. Meiller S, Schaffie J, Poschenrieder F, et al. Can CT performed in the
early disease phase predict outcome of patients with COVID-19 pneu-
monia? Analysis of a cohort of 64 patients from Germany. Eur J Radiol 2020;
131:109256.
24. Mozafari A, Miladinia M, Sabri A, et al. The challenge of deciding
between home-discharge versus hospitalization in COVID-19 patients:
The role of initial imaging and clinical/ laboratory data. Clin Epidemiol Glob
Health 2021; 10:100673.
25. Mruk B, Walecki J, Gorecki A, et al. Chest computed tomography (CT) as
a predictor of clinical course in coronavirus disease. Med Sci Monit
2021; 27:e931285.
26. Satici C, Cengel F, Gurkan O, et al. Mediastinal lymphadenopathy may
predict 30-day mortality in patients with COVID-19. Clin Imaging 2021;
75:119–124.
27. Sattarzadeh Badkoubi R, Khoshavi M, Laleh Far V, et al. Imaging data
in COVID-19 patients: focused on echocardiographic findings. Int J Cardi-
diaco Imaging 2021; 37:1629–1636.
28. Schiaffino S, Albano D, Cozzi A, et al. CT-derived chest muscle metrics
for outcome prediction in patients with COVID-19. Radiology 2021;204141.
29. Scoccia A, Gallone G, Cereda A, et al. Impact of clinical and subclinical
coronary artery disease as assessed by coronary artery calcium in
COVID-19. Atherosclerosis 2021; 328:136–143.
30. Slipczuk L, Castagna F, Schonberger A, et al. Coronary artery calcifica-
tion and epidural adipose tissue as independent predictors of mortality
in COVID-19. Int J Cardiovasc Imaging 2021; 1–8.
31. Tabatabaiei SMH, Talayi H, Moghaddas F, et al. CT Features and short-
term prognosis of COVID-19 pneumonia: a single-center study from kashan,
Iran. Radiol Cardiothorac Imaging. 2020; 2:e00130.
32. Tabatabaie MMH, Rahimi H, Moghaddas F, et al. Predictive value of CT in
the short-term mortality of coronavirus disease 2019 (COVID-19) pneu-
monia in nonelderly patients: a case-control study. Eur J Radiol 2020;
132:109298.
33. Wei XS, Wang X, Ye L, et al. Pleural effusion as an indicator for the poor
prognosis of COVID-19 patients. Int J Clin Pract 2021; 75:e14123.
34. Zhan N, Guo Y, Tian S, et al. Clinical characteristics of COVID-19 compli-
cated with pleural effusion. BMC Infect Dis 2021; 21:176.
35. Zimmermann GS, Fingerle AA, Müller-Leisse C, et al. Coronary calcium
scoring assessed on native screening chest CT imaging as predictor for
outcome in COVID-19: An analysis of a hospitalized German cohort.
PLoS One 2020; 15:e0244707.
36. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in meta-analyses -
2008. Accessed from: http://www.ohri.ca/programs/clinical_epidemiol-
ogy/oxford.asp Accessed July 1, 2021.
37. Leeflang MM, Deeks JJ, Gatsuonis C, et al. Systematic reviews of diag-
nostic test accuracy. Ann Intern Med 2008; 149:889–897.
38. Zambra J, Abraira V, Muriel A, et Meta-DisC: a software for meta-anal-
ysis of test accuracy data. BMC Med Res Methodol 2006; 6:31.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
1986; 7:177–188.
40. Zeng Z, Wu C, Lin Z, et al. Development and validation of a simple-to-use
nomogram to predict the deterioration and survival of patients with
COVID-19. BMC Infect Dis 2021; 21:356.
40. Gallo Marin B, Aghagoli G, Lavine K, et al. Predictors of COVID-19 severity: a literature review. Rev Med Virol 2021; 31:1–10.
41. Hassanipour S, Azadbakht O, Dehnavi Z, et al. Meta-analysis: COVID-19 diagnosis in chest CT—master key for radiologists. Egypt J Radiol Nucl Med 2021; 52:86.
42. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–1062.
43. Wong HYF, Lam HYS, Fong AH, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. Radiology 2020; 296:E72–E78.
44. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One 2020; 15:e0241955.
45. Chen Q, Xu L, Dai Y, et al. Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol 2020; 43:796–802.
46. Gray WK, Navaratnam AV, Day J, et al. Changes in COVID-19 in-hospital mortality in hospitalised adults in England over the first seven months of the pandemic: an observational study using administrative data. Lancet Reg Health Eur 2021; 5:100104.